The response of certain dermatologic diseases to sulfanilamide is well established, and the literature on the subject has been adequately reviewed. Because sulfathiazole1 appeared to be more effective than sulfanilamide for streptococcic infections,2 on a par with sulfapyridine for pneumococcic infections3 and superior to both for staphylococcic infections,4 the clinical trial of sulfathiazole in the treatment of certain dermatologic diseases seemed to be indicated, particularly for those in which staphylococci or streptococci are etiologically concerned.
This paper submits data on the clinical effectiveness and the toxic side effects of sulfathiazole which justify a trend toward the use of this drug. The decision as to the choice of drug must, of course, be based on the proper evaluation of sufficient accumulated data.
CLINICAL OBSERVATIONS WITH SULFATHIAZOLE
A total of 103 patients were treated with sulfathiazole, 58 of whom had failed to respond to other forms of treatment.